We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+1.14%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$610M
AUM Growth
+$126M
(+26%)
Cap. Flow
+$157M
Cap. Flow
% of AUM
25.76%
Top 10 Holdings %
Top 10 Hldgs %
65.04%
Holding
54
New
16
Increased
19
Reduced
10
Closed
8
Avg Time Held
3.7
quarters
Top 10 Avg Time Held
3.9
quarters
Top 20 Avg Time Held
4.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$46.8M |
| 2 |
GeneDx Holdings
WGS
|
+$42.7M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$20M |
| 4 |
Alkermes
ALKS
|
+$15.9M |
| 5 |
Procept Biorobotics
PRCT
|
+$15.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Icon
ICLR
|
+$20M |
| 2 |
Amicus Therapeutics
FOLD
|
+$16.4M |
| 3 |
Select Medical
SEM
|
+$15.4M |
| 4 |
Roivant Sciences
ROIV
|
+$11.5M |
| 5 |
Avantor
AVTR
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.84% |
| 2 | Industrials | 0.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Nektar Therapeutics
NKTR
$1.29B
| $52.9M | 8.67% |
735,000
+180,367
| +33% | +$10.3M |
2025 Q4
1 quarter
|
|
|
2
Boston Scientific
BSX
$62.8B
| $49.9M | 8.19% |
795,547
+585,547
| +279% | +$46.8M |
2025 Q3
2 quarters
|
|
3
Janux Therapeutics
JANX
$1.05B
| $49.3M | 8.09% |
3,550,000
+1,157,477
| +48% | +$15.9M |
2024 Q3
6 quarters
|
|
|
4
Procept Biorobotics
PRCT
$1.09B
| $48.6M | 7.98% |
1,945,000
+565,000
| +41% | +$15.9M |
2025 Q3
2 quarters
|
|
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
| $46.5M | 7.63% |
1,550,000
+475,888
| +44% | +$15.8M |
2021 Q1
20 quarters
|
|
|
6
GeneDx Holdings
WGS
$1.94B
| $33.6M | 5.51% |
523,463
+468,463
| +852% | +$42.7M |
2025 Q4
1 quarter
|
|
7
Shattuck Labs
STTK
$551M
| $32.2M | 5.28% |
5,004,439
+2,622,937
| +110% | +$12.4M |
2021 Q3
18 quarters
|
|
8
ADC Therapeutics
ADCT
$217M
| $31.1M | 5.1% |
8,300,000
-177,338
| -2% | -$699K |
2022 Q3
14 quarters
|
|
9
Kura Oncology
KURA
$874M
| $27.3M | 4.48% |
3,356,700
+827,100
| +33% | +$7.11M |
2023 Q2
11 quarters
|
|
|
10
Alnylam Pharmaceuticals
ALNY
$29.9B
| $25.1M | 4.12% |
76,000
+58,891
| +344% | +$20M |
2025 Q4
1 quarter
|
|
11
MeiraGTx Holdings
MGTX
$955M
| $22.8M | 3.73% |
2,629,971
-579,817
| -18% | -$4.4M |
2022 Q1
16 quarters
|
|
|
12
Alkermes
ALKS
$6.67B
| $18.2M | 2.98% |
+513,632
| New | +$15.9M |
2026 Q1
0 quarters
|
|
13
Syndax Pharmaceuticals
SNDX
$1.25B
| $18M | 2.95% |
770,000
+105,000
| +16% | +$2.28M |
2024 Q2
7 quarters
|
|
14
Veeva Systems
VEEV
$48.8B
| $15.2M | 2.49% |
86,480
-3,653
| -4% | -$718K |
2025 Q4
1 quarter
|
|
15
Zymeworks
ZYME
$1.8B
| $13.5M | 2.21% |
539,049
+8,656
| +2% | +$205K |
2024 Q1
8 quarters
|
|
16
DELISTED
Crinetics Pharmaceuticals
CRNX
| $12.7M | 2.08% |
350,000
+87,096
| +33% | +$3.89M |
2025 Q2
3 quarters
|
|
17
Abivax
ABVX
$7.52B
| $11.7M | 1.92% |
105,000
+88,000
| +518% | +$10.4M |
2025 Q4
1 quarter
|
|
18
Concentra Group Holdings
CON
$4.79B
| $10.8M | 1.78% |
505,822
-385,208
| -43% | -$8.57M |
2025 Q2
3 quarters
|
|
19
DELISTED
Terns Pharmaceuticals
TERN
| $10.7M | 1.75% |
202,300
+107,300
| +113% | +$4.41M |
2025 Q4
1 quarter
|
|
20
Phreesia
PHR
$667M
| $9.22M | 1.51% |
1,100,000
+122,848
| +13% | +$1.62M |
2025 Q4
1 quarter
|
|
21
OnKure Therapeutics
OKUR
$95.2M
| $8.92M | 1.46% |
2,154,381
+1,337,472
| +164% | +$4.13M |
2024 Q4
5 quarters
|
|
22
Corbus Pharmaceuticals
CRBP
$92.5M
| $6.55M | 1.07% |
697,108
+13,236
| +2% | +$111K |
2024 Q3
6 quarters
|
|
23
Schrodinger
SDGR
$1.94B
| $5.8M | 0.95% |
+510,578
| New | +$7.06M |
2026 Q1
0 quarters
|
|
24
Emergent Biosolutions
EBS
$354M
| $5.3M | 0.87% |
+639,118
| New | +$6.62M |
2026 Q1
0 quarters
|
|
|
25
Roivant Sciences
ROIV
$24.1B
| $4.99M | 0.82% |
180,000
-447,162
| -71% | -$11.5M |
2024 Q1
8 quarters
|
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q1 2026 Portfolio in Review
As of Q1 2026, Prosight Management held 54 positions worth $610M, up 26% from $484M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Prosight Management deployed $157M of net new capital in Q1 2026, opening 16 new positions and adding to 19 existing holdings. Its largest new stake was Alkermes: 513,632 shares worth $18.2M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was Roivant Sciences, an estimated $11.5M trimmed.
- Prosight Management's largest Q1 2026 buy was Alkermes: 513,632 shares worth $18.2M.
- Prosight Management added most to Boston Scientific in Q1 2026, an estimated $46.8M increase.
- Prosight Management's biggest Q1 2026 reduction was Roivant Sciences, cutting an estimated $11.5M.
- Prosight Management fully exited Icon in Q1 2026, selling an estimated $20M.
- Prosight Management's ten largest holdings make up 65% of its $610M portfolio in Q1 2026.
- Prosight Management opened 16 new positions and closed 8 in Q1 2026.
- Prosight Management's portfolio value rose 26% quarter-over-quarter to $610M.
Based on Prosight Management's 13F filing for Q1 2026, filed 15 May 2026.